These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19336514)

  • 1. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.
    Walvoord EC; de la Peña A; Park S; Silverman B; Cuttler L; Rose SR; Cutler G; Drop S; Chipman JJ
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2052-9. PubMed ID: 19336514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
    Underwood LE; Attie KM; Baptista J;
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5273-80. PubMed ID: 14602761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian variation in the pharmacokinetics of steady state continuous subcutaneous infusion of growth hormone in adult growth hormone deficient patients.
    Janukonyté J; Parkner T; Lauritzen T; Christiansen JS; Laursen T
    Growth Horm IGF Res; 2013 Dec; 23(6):256-60. PubMed ID: 24094495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.
    Cohen P; Rogol AD; Howard CP; Bright GM; Kappelgaard AM; Rosenfeld RG;
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2480-6. PubMed ID: 17356043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
    J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial.
    Hoffman AR; Kuntze JE; Baptista J; Baum HB; Baumann GP; Biller BM; Clark RV; Cook D; Inzucchi SE; Kleinberg D; Klibanski A; Phillips LS; Ridgway EC; Robbins RJ; Schlechte J; Sharma M; Thorner MO; Vance ML
    J Clin Endocrinol Metab; 2004 May; 89(5):2048-56. PubMed ID: 15126520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
    Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency.
    Bidlingmaier M; Kim J; Savoy C; Kim MJ; Ebrecht N; de la Motte S; Strasburger CJ
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2926-30. PubMed ID: 16720652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent changes in body composition during growth hormone (GH) treatment in Japanese patients with adult GH deficiency: a randomized, placebo-controlled trial.
    Chihara K; Fujieda K; Shimatsu A; Miki T; Tachibana K
    Growth Horm IGF Res; 2010 Jun; 20(3):205-11. PubMed ID: 20176498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
    Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
    Teichman SL; Neale A; Lawrence B; Gagnon C; Castaigne JP; Frohman LA
    J Clin Endocrinol Metab; 2006 Mar; 91(3):799-805. PubMed ID: 16352683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first-in-man phase 1 trial for long-acting TransCon Growth Hormone.
    Gilfoyle D; Mortensen E; Christoffersen ED; Leff JA; Beckert M
    Growth Horm IGF Res; 2018 Apr; 39():34-39. PubMed ID: 29273485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency.
    Khadilkar V; Radjuk KA; Bolshova E; Khadgawat R; El Kholy M; Desai M; Peterkova V; Mericq V; Kratzsch J; Siepl EC; Martin D; Lopez P; Ji HJ; Bae YJ; Lee JH; Saenger PH
    J Clin Endocrinol Metab; 2014 Jan; 99(1):126-32. PubMed ID: 24170106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of beta 1-adrenergic blockade on the growth response to growth hormone (GH)-releasing hormone therapy in GH-deficient children.
    Cassorla F; Mericq V; García H; Cristiano A; Avila A; Boric A; Iñiguez G; Merriam GR
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2997-3001. PubMed ID: 7559887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
    Keller A; Wu Z; Kratzsch J; Keller E; Blum WF; Kniess A; Preiss R; Teichert J; Strasburger CJ; Bidlingmaier M
    Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.